Last updated on July 2017

B HLMANN fCAL ELISA - Aid in Differentiation of IBD From IBS


Brief description of study

The purpose of this study is to confirm the sensitivity and specificity of the BÜHLMANN fCAL™ ELISA as an aid in diagnosis to differentiate between Inflammatory Bowel Disease (IBD; Crohn's Disease (CD), Ulcerative Colitis (UC), or indeterminate colitis) and Irritable Bowel Syndrome (IBS). To estimate the predictive value of a positive test (positive predictive value (PPV)) and the predictive value of a negative test (Negative Predictive Value (NPV)) using the proposed test outcomes for BÜHLMANN Calprotectin Test results when used in patients referred for diagnostic evaluation with signs and symptoms suggestive of either IBS or IBD. To confirm the inter-laboratory consistency of test results for the BÜHLMANN fCAL™ ELISA. To provide exploratory observations of test results in patients between the age of 2 and 21 years. To provide a sample set from normal subjects with no symptoms or signs of gastrointestinal disease for use in Expected Value Testing.

Clinical Study Identifier: NCT02351635

Contact Investigators or Research Sites near you

Start Over

KT Park, MD

Stanford Center for Clinical & Translational Research & Education
Palo Alto, CA United States
  Connect »

James Leavitt, MD

Gastro Health
Miami, FL United States
  Connect »

Shahriar Sedghi, MD

Gastroenterology Assocaites of Central Georgia
Macon, GA United States
  Connect »

Eugene Greenberg, MD

Carle Foundation, Center for Digestive and Liver Disease
Urbana, IL United States
  Connect »

Anthony Lembo, MD

Beth israel Deaconess Medical Center
Boston, MA United States
  Connect »

Keith Friedenberg, MD

Great Lakes Gastroenterology Research, LLC.
Mentor, OH United States
  Connect »

Felix Tiongco, MD

Gastroenterology Associates of Tidewater
Chesapeake, VA United States
  Connect »